Limosilactobacillus reuteri 6475 and Prevention of Early Postmenopausal Bone Loss: A Randomized Clinical Trial
Summary
Daily supplementation with the probiotic Limosilactobacillus reuteri ATCC PTA 6475 (L reuteri) was tested against a placebo to reduce early postmenopausal bone loss in women aged 50 to 60 years over a 2-year period. The study aimed to evaluate the potential skeletal benefits of long-term treatment with L reuteri.
Key Findings
The trial involved 239 postmenopausal women and found that supplementation with L reuteri did not have a significant effect on bone loss or bone turnover over the 2-year period. However, a significant interaction was observed between body mass index (BMI) and treatment effect, indicating the need for further investigation.
Practical Solutions and Value
Clinical trials are essential for developing safe and effective treatments. Our AI-driven platform, DocSym, consolidates clinical standards and research, making it easier for clinicians to access relevant knowledge. Additionally, our mobile apps support scheduling, treatment monitoring, and telemedicine, streamlining operations and enhancing patient care in today’s healthcare environment.
AI technology can improve clinic workflows and patient outcomes while reducing paper-based routines. Learn more about how our solutions can benefit your practice at aidevmd.com.
